Menopause searches bring up a wide range of peptide claims, and this page exists mainly to say plainly where the evidence actually stands: nowhere close to an approved treatment. No peptide sold anywhere is approved for hot flashes, sleep disruption, mood changes or vaginal dryness at menopause. What does have real research behind it, for the two things people most often ask about at midlife, weight gain and skin, is a set of approved medicines and one cosmetic ingredient that were never tested specifically in a menopausal population. This guide covers what those studies actually found and is not a substitute for a conversation about hormone therapy with a physician.
Summary
| Compound | Best evidence | Stage |
|---|---|---|
| Semaglutide Stocked locally | Large human RCTs for weight loss (STEP-1) and cardiovascular outcomes (SELECT), general adult population | Approved medicine (Ozempic, Wegovy); not studied specifically in menopausal women |
| Tirzepatide Stocked locally | SURMOUNT-1, a large human RCT with the largest reported weight loss of the three GLP-1 drugs here | Approved medicine (Mounjaro, Zepbound); not studied specifically in menopausal women |
| Liraglutide | SCALE (weight loss) and LEADER (cardiovascular outcomes), the longest track record in the class | Approved medicine (Victoza, Saxenda); not studied specifically in menopausal women |
| GHK-Cu (topical) Stocked locally | Small 8 to 12 week human cosmetic studies on facial and eye skin | Cosmetic ingredient; not tested for menopause-related skin changes specifically |
Why menopause searches land here at all
Menopause brings a sharp drop in oestrogen, and two of its most visible knock-on effects are a shift in body weight and fat distribution, and changes in skin quality as collagen production slows. Neither of those is unique to menopause, which is exactly why the compounds people search for are general-purpose weight and skin products rather than anything built around the hormonal transition itself. None of the four compounds below was designed as a menopause treatment, and none of their pivotal trials reported results specifically for perimenopausal or postmenopausal participants.
Semaglutide, tirzepatide and liraglutide: approved for weight, not for menopause
These three GLP-1 receptor agonists have the deepest human evidence base of anything discussed on this page, and it is worth being precise about what that evidence covers. Semaglutide's STEP-1 trial ran 68 weeks in adults with obesity or overweight and reported a mean weight loss of 14.9% against 2.4% on placebo; its SELECT trial then tested the same dose in 17,604 adults with cardiovascular disease. Tirzepatide's SURMOUNT-1 trial reported mean weight loss up to 20.9% at 72 weeks, the largest figure among approved drugs in this group. Liraglutide has the longest track record, with its SCALE weight trial and its LEADER cardiovascular outcomes trial both published in the 2010s.
All three are legitimate, approved medicines, sold in Philippine pharmacies as Ozempic, Wegovy, Mounjaro, Victoza and Saxenda, and prescribing belongs with a licensed Philippine physician. What none of them offers is trial evidence specific to menopause. Their study populations were defined by weight, diabetes status or cardiovascular risk, not by menopausal stage, and none is approved for a menopause-related indication. Anyone considering one of these drugs for weight gain that coincides with midlife should treat that as a conversation about weight management with a physician, not as a menopause treatment. The best peptides for muscle growth and fat loss guide covers the full comparison across this drug class, including retatrutide, which remains investigational and unapproved anywhere.
GHK-Cu (topical): studied for skin, not for the menopause transition
Topical GHK-Cu, the copper-binding tripeptide sold as a cosmetic ingredient, has a real if modest human evidence base: 8 to 12 week studies in women with photoaging reported improved skin density, firmness and fewer fine lines compared with placebo or comparator creams. Its proposed mechanism, supporting collagen production through a copper-dependent pathway, is relevant in principle to the slower collagen turnover that follows the drop in oestrogen at menopause, but no cited study selected participants by menopausal status or measured that specific mechanism. It is a general skin-quality ingredient with cosmetic-study evidence, not a menopause-skin therapy with its own trial. FDA Philippines regulates finished GHK-Cu creams as cosmetics, not as drugs. The best peptides for skin guide ranks it against argireline and SNAP-8 for general skin-quality evidence.
Kisspeptin: relevant biology, no menopause trial
Kisspeptin sits at the top of the reproductive hormone axis, the same axis that winds down at menopause as the ovaries stop responding the way they did earlier in life. That makes it a biologically reasonable thing to search for, but the actual human research on kisspeptin has gone in a different direction: small trials measuring hormone release in healthy men, and separate trials testing brain responses to sexual imagery in premenopausal women and men with low sexual desire. None of that research involved menopausal women, and no trial has tested kisspeptin for hot flashes, sleep, mood or any other menopause symptom. See the kisspeptin page for its actual trial record.
What this page does not cover, on purpose
Hormone replacement therapy, whether oestrogen, progesterone or a combination, is the established, physician-prescribed option for menopause symptoms and sits outside the scope of a peptide research site. So do non-hormonal prescription medicines a physician might discuss for hot flashes or mood. Nothing here should be read as an alternative to that conversation. If menopause symptoms are affecting daily life, the first call is a licensed Philippine physician who can weigh personal and family medical history, something no guide like this one can do.
Safety notes
Semaglutide, tirzepatide and liraglutide all carry a boxed warning about thyroid C-cell tumours seen in rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2; gastrointestinal effects such as nausea and diarrhoea are the most commonly reported issues across their trials. Topical GHK-Cu's cosmetic studies reported no serious adverse effects, with mild redness or stinging possible alongside other active ingredients. See side effect management for the wider picture on the GLP-1 class, and bloodwork in the Philippines for what monitoring on any of these typically involves.
Status in the Philippines
Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) and liraglutide (Victoza, Saxenda) are all registered prescription medicines sold in Philippine pharmacies; see cost reality in the Philippines for pharmacy pricing. Topical GHK-Cu products are sold locally as cosmetics, regulated as such by FDA Philippines, with no approved medical indication. Kisspeptin is not registered with FDA Philippines and is available only through research-peptide sellers, with no established use for anything discussed on this page.
